|
| Press Releases |
|
 |
|
| Monday, November 12, 2018 |
|
|
Eisai Launches Lenvima (Lenvatinib) in China |
| Eisai Co., Ltd. announced that its Chinese subsidiary Eisai China Inc. (ECI) has launched the kinase inhibitor LENVIMA (generic name: lenvatinib mesylate) in China. more info >> |
|
| Friday, November 9, 2018 |
|
|
エーザイとMSD、「レンビマ」(レンバチニブ)と「キイトルーダ」(ペムブロリズマブ)との併用療法について3がん腫に対する最新の研究成果を第33回がん免疫学会年次総会にて発表 |
| エーザイとMSD、「レンビマ」(レンバチニブ)と「キイトルーダ」(ペムブロリズマブ)との併用療法について3がん腫に対する最新の研究成果を第33回がん免疫学会年次総会にて発表 more info >> |
|
|
Eisai: New Data from Investigational Study of Lenvima (Lenvatinib) and Keytruda (Pembrolizumab) Combination in Three Different Tumor Types Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting |
| Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A., known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA, an orally available kinase inhibitor discovered by Eisai, in combination with Merck's & Co., Inc.'s anti-PD-1 therapy KEYTRUDA in three different tumor types - metastatic non-small cell lung cancer (NSCLC), metastatic melanoma and metastatic urothelial carcinoma. more info >> |
|
| Wednesday, June 13, 2018 |
|
|
エーザイ、新規の核酸合成とデリバリー技術を用いた核酸創薬研究に関する産学官共同研究開発契約を締結し、研究活動を開始 |
| エーザイ株式会社は、このたび、当社の研究子会社である株式会社カン研究所を代表とする研究プロジェクト「新規の核酸合成とデリバリー技術を用いた核酸創薬研究」について、カン研究所と6つの共同研究機関＊との間で産学官共同研究開発契約を締結しましたのでお知らせします。 more info >> |
|
| Thursday, November 8, 2018 |
|
|
Eisai: Industry-Academia-Government Joint Development Agreement Concerning Anti-Fractalkine Antibody E6011 for Treatment of Crohn's Disease Concluded, Research Activities Commence |
| Eisai Co., Ltd. and Eisai's subsidiary for gastrointestinal diseases EA Pharma Co., Ltd. announced today that EA Pharma has entered into an industry-academia-government joint research agreement with six related joint research organizations, and that research activities have fully commenced. more info >> |
|
|
エーザイとEAファーマ、抗フラクタルカイン抗体E6011のクローン病治療薬開発で産学官連携の契約を締結し、研究開発を開始 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下エーザイ）とエーザイの消化器事業子会社であるEAファーマ株式会社（本社：東京都、代表取締役社長：松江裕二、以下EAファーマ）は、E6011のクローン病治療薬開発において、EAファーマと6つの共同研究機関との間で研究委受託契約を締結し、研究開発を本格的に開始しましたのでお知らせします。 more info >> |
|
|
エーザイ、中国の新蘇州工場が本格稼働 |
| エーザイ株式会社（本社：東京都、代表執行役 CEO：内藤晴夫）は、このたび、中国子会社である衛材（中国）薬業有限公司（Eisai China Inc.）が、蘇州工業園区内の新蘇州工場の本格稼働に伴い、オープニングセレモニーを開催しましたのでお知らせします。 more info >> |
|
|
Eisai Commences Full-Scale Operation of New Suzhou Plant in China |
| Eisai Co., Ltd. announced today that its Chinese subsidiary, Eisai China Inc. (ECI) has commenced full-scale operation of its new Suzhou plant located within the Suzhou Industrial Park, and an opening ceremony was held accordingly. more info >> |
|
| Monday, October 29, 2018 |
|
|
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD |
| Biogen and Eisai Co., Ltd. announced that Biogen presented results at the Clinical Trials on Alzheimer's Disease (CTAD) meeting, in Barcelona, Spain, from the recent 36- and 48-month analyses of the ongoing long-term extension (LTE) of the Phase 1b study of aducanumab, an investigational treatment for mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD. more info >> |
|
| Friday, October 26, 2018 |
|
|
エーザイ、アルツハイマー病に伴う不規則睡眠覚醒リズム障害を対象とする「レンボレキサント」の最新データを第11回アルツハイマー病臨床試験会議（CTAD）において発表 |
| エーザイ、アルツハイマー病に伴う不規則睡眠覚醒リズム障害を対象とする「レンボレキサント」の最新データを第11回アルツハイマー病臨床試験会議（CTAD）において発表 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
華住公佈2024年第一季度財報 收入增長17.8%优于预期
May 17, 2024 22:39 HKT/SGT
|
|
|
H World Group Limited Reports Q1 2024 Financial Results with 17.8% Revenue Growth, Surpassing Expectation
May 17, 2024 22:29 HKT/SGT
|
|
|
Top executives from SDAIA, Saudi Aramco, Almarai, Saudi Pro League & many others coming to speak at Smart Data & AI Summit
May 17, 2024 20:09 HKT/SGT
|
|
|
卓悦集团附属公司与“湖南广电芒果超媒”旗下“快乐购”签署战略合作备忘录
May 17, 2024 20:00 HKT/SGT
|
|
|
卓悅集團附屬公司與「湖南廣電芒果超媒」旗下「快樂購」簽署戰略合作備忘錄
May 17, 2024 19:43 HKT/SGT
|
|
|
Raytech Holding: Making Nasdaq Debut as It Pioneers Personal Care Electrical Appliances in a Booming Market
May 17, 2024 18:00 HKT/SGT
|
|
|
中信国际电讯CPC守正创新 AI创新方案喜迎两大奖
May 17, 2024 17:04 HKT/SGT
|
|
|
中信國際電訊CPC守正創新 AI創新方案喜迎兩大獎
May 17, 2024 16:55 HKT/SGT
|
|
|
CITIC Telecom CPC's Innovation Excellence Honored with 2 Innovation Awards
May 17, 2024 16:37 HKT/SGT
|
|
|
London Climate Technology Show 2024 Returns For Third Edition at ExCeL London
May 17, 2024 15:48 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
Sri Trang (SET: STA) announces delivery of EUDR rubber to customers
May 17, 2024 15:00 HKT/SGT
|
|
|
富士通、論理推論を可能とする大規模言語モデルの研究開発が「GENIAC」に採択
May 17, 2024 14:00: JST
|
|
|
Fujitsu chosen for GENIAC project, starts development of large language models for logical reasoning
May 17, 2024 14:03 JST
|
|
|
NEC Leverages RISE with SAP and AI to Build Business AI in Move to the Cloud
May 17, 2024 11:19 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
